LINC00852 and breast cancer: The pan-cancer analysis performed through the GENT2 database also demonstrated a significant upregulation of LINC00852 in lung cancer, and its remarkable downregulation in many tumors including brain, head and neck, esophagus, kidney, endometrium, stomach, tongue, thyroid, uterus and specially breast cancer (Fig. 1).